Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 in renal impairment
NCT06845813Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenbelintide (5 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity and 1 more. Started Feb 2025; status: completed.
02
Drugs
lenbelintide
Beyond the preview
Go deeper on NCT06845813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845813.